Free Trial
→ Every Starlink dish pays this stock (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.14
-13.8%		$0.33
$0.11
▼
$95.50
$3.11M-2.19199,545 shs932,537 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KALA BIO, Inc. stock logo
KALA
KALA BIO
-13.79%-10.97%-26.17%-85.39%-99.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.14
-13.8%		$0.33
$0.11
▼
$95.50
$3.11M-2.19199,545 shs932,537 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KALA BIO, Inc. stock logo
KALA
KALA BIO
-13.79%-10.97%-26.17%-85.39%-99.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
KALA BIO, Inc. stock logo
KALA
KALA BIO
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/A$12.56 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$26.98M-$31.96N/AN/AN/AN/A-222.35%-70.23%N/A

Latest KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$6.00-$21.32-$15.32-$21.32$25.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A
6.88
6.88

Institutional Ownership

CompanyInstitutional Ownership
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%

Insider Ownership

CompanyInsider Ownership
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
619.34 million18.91 millionNot Optionable

Recent News About These Companies

KALA BIO Reports Delay in Quarterly Filing
November 13 at 5:31 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kala-bio-reports-delay-in-quarterly-filing?utm_source=marketbeat.com&utm_medium=referral
KALA BIO announces 1-for-30 reverse stock split
November 12 at 11:16 AM  |  msn.comhttps://www.msn.com/en-us/news/other/kala-bio-announces-1-for-30-reverse-stock-split/ar-AA2higxA
KALA BIO Announces Reverse Stock Split
November 12 at 8:00 AM  |  newsfilecorp.comN
KALA BIO, Inc. Narrows Preliminary Q3 Net Loss to About $0.8 Million
November 10, 2026  |  tokenpost.comT
KALA BIO, Inc. Narrows Preliminary Q3 Net Loss to About $0.8 Million
November 10, 2026  |  tokenpost.comT
KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
November 9, 2026  |  newsfilecorp.comN
KALA BIO (KALA) Set to Post Quarterly Earnings on Tuesday
November 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31187060
Kala Bio Inc KALA
November 3, 2026  |  morningstar.comM
KALA BIO stock targets telehealth expansion with a USD 15.00 million LOI
September 30, 2026  |  ad-hoc-news.deA
KALA Bio Signs LOI To Acquire Nationwide Telehealth Platform; Shares Rise
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695210/kala-bio-signs-loi-to-acquire-nationwide-telehealth-platform-shares-rise.aspx
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
September 29, 2026  |  newsfilecorp.comN
Kala Bio, Inc. And Virotek Inc. Sign Letter Of Intent With U.S. DNA Testing Platform To Resell Virotek Inc.'s Suite Of Genetic Testing Products
September 25, 2026  |  marketscreener.comM
Kala Bio, Inc. und Virotek Inc. unterzeichnen Absichtserklärung mit einer US-amerikanischen DNA-Testplattform zum Weiterverkauf der genetischen Testproduktpalette von Virotek Inc.
September 25, 2026  |  de.marketscreener.comD
Kala Bio And Virotek Sign LOI To Expand Genetic Testing Distribution
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693677/kala-bio-and-virotek-sign-loi-to-expand-genetic-testing-distribution.aspx
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368214/0/en/kala-bio-and-virotek-sign-letter-of-intent-with-u-s-dna-testing-platform-to-resell-virotek-s-suite-of-genetic-testing-products.html
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3363873/0/en/kala-bio-adds-healthcare-operator-yenvy-truong-to-advisory-team.html
Kala Bio signs exclusive US distribution agreement for Virotek ophthalmology genetic tests
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/kala-bio-signs-exclusive-us-distribution-agreement-for-virotek-ophthalmology-genetic-tests/ar-AA2bvf5Z
KALA stock falls after reverse split as Kala Bio pursues ophthalmology partnerships
September 3, 2026  |  ad-hoc-news.deA
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355914/0/en/kala-bio-and-virotek-finalize-definitive-agreement-establishing-exclusive-u-s-distribution-partnership-for-ophthalmology-genetic-testing-program.html
KALA BIO, Inc. (KALA) Stock Price, News, Quote & History - Yahoo Finance
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/KALA/latest-news/

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$0.14 -0.02 (-13.79%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.14 0.00 (-2.02%)
As of 11/13/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas